Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02909088
Other study ID # EcoUCR001
Secondary ID IND 128278
Status Recruiting
Phase Phase 2/Phase 3
First received August 25, 2016
Last updated October 24, 2016
Start date September 2016
Est. completion date November 2017

Study information

Verified date October 2016
Source CITrials
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the efficacy and tolerability of ecopipam in reducing stuttering symptoms.

It is hypothesized that ecopipam effectively reduces stuttering symptoms as measured on the SSI-IV total score, the CGI, SSS and OASES.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date November 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

Subjects can be enrolled in the study only if they meet all of the following criteria:

1. Subjects must satisfy DSM-IV criteria for childhood onset fluency disorder (stuttering).

2. The nature of stuttering must be developmental in origin with the onset prior to ten years of age.

3. Subjects must have a score of moderate or higher on the SSI-IV.

4. Women of child-bearing potential are eligible to participate as long as they are practicing a medically accepted form of contraception (i.e. condom with spermicide or diaphragm, oral or depot contraception, or an intrauterine device).

5. Subjects will be male or female from the ages of 18-60.

6. Subject must have a MADRS total score of = 13 (normal mood)

7. Subjects will be of only English speaking.

Exclusion Criteria:

Subjects will be excluded from the study for any of the following reasons:

1. Adult individuals who lack capacity to consent for themselves.

2. Stuttering related to a known neurologic cause (e.g. head trauma, stroke).

3. Unstable medical or psychiatric illness.

4. Active substance abuse within three months prior to study inclusion.

5. Any illness that would require the concomitant use of a CNS active medication during the course of the study.

6. Subjects with Parkinson's dementia or other degenerative neurologic illness.

7. Suffer from irregular heart rate or seizures

8. Subjects who are pregnant or nursing an infant.

9. Subject with a MADRS = 14

10. Breastfeeding a child during the course of the study or for one month following completion

11. It is the investigator's opinion that the subject poses a significant suicide risk by the following criteria:

1. It is the investigator's opinion that the subject may be at risk of suicide.

2. the subject responds "yes" to question #4 (Active Suicidal Ideation with Specific Plan and Intent) on the Baseline Visit of the Columbia Suicide Severity Rating Scale (C-SSRS), if the most recent episode occurred within the past 12 months.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Ecopipam 50mg

Ecopipam 100mg


Locations

Country Name City State
United States CITrials Riverside California
United States University of California Riverside School of Medicine Riverside California

Sponsors (2)

Lead Sponsor Collaborator
Gerald Maguire, MD University of California Riverisde School of Medicine

Country where clinical trial is conducted

United States, 

References & Publications (7)

Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE. A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol. 2014 Jan-Feb;37(1):26-30. doi: 10.1097/WNF.0000000000000017. — View Citation

Maguire G, Franklin D, Vatakis NG, Morgenshtern E, Denko T, Yaruss JS, Spotts C, Davis L, Davis A, Fox P, Soni P, Blomgren M, Silverman A, Riley G. Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: the EXamining Pa — View Citation

Maguire GA, Riley GD, Franklin DL, Gottschalk LA. Risperidone for the treatment of stuttering. J Clin Psychopharmacol. 2000 Aug;20(4):479-82. — View Citation

Maguire GA, Riley GD, Franklin DL, Maguire ME, Nguyen CT, Brojeni PH. Olanzapine in the treatment of developmental stuttering: a double-blind, placebo-controlled trial. Ann Clin Psychiatry. 2004 Apr-Jun;16(2):63-7. — View Citation

Maguire GA, Riley GD, Yu BP. A neurological basis of stuttering? Lancet Neurol. 2002 Nov;1(7):407. Review. — View Citation

Maguire GA, Yu BP, Franklin DL, Riley GD. Alleviating stuttering with pharmacological interventions. Expert Opin Pharmacother. 2004 Jul;5(7):1565-71. Review. — View Citation

Riley J, Riley G, Maguire G. Subjective Screening of Stuttering severity, locus of control and avoidance: research edition. J Fluency Disord. 2004;29(1):51-62. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the Stuttering Severity Instrument Version IV (SSI-IV) This is an objective measure of stuttering in which it captures verbal samples of five minutes speaking during a conversation and 5 minutes of reading a passage. This scale is completed on Visit 1/screening and Visit 5/week 8. No
Secondary Clinical Global Impression Scale-Severity (CGI-S) This is an evaluation of the patient by the investigator as to whether or not the subjects has improved, remained the same, or worsened while in the study. This scale is completed on Visit 1/screening, Visit 2/baseline, Visit 3/week 2, and Visit 5/week 8. No
Secondary Subjective Stuttering Scale (SSS) This scale is completed on Visit 2/baseline and Visit 5/week 8. No
Secondary Overall Assessment of the Speaker's Experience of Stuttering (OASES) This scale is completed on Visit 2/baseline and Visit 5/week 8. No
Secondary Montgomery Asberg Depression Rating Scale (MADRS) An observer-rated depression scale This scale is completed on Visit 2/baseline, Visit 3/week 2, Visit 4/week 4 and Visit 5/week 8. Yes
Secondary Barnes Akathisia Scale (BAS) measures how restless the subject is during the examination This scale is completed on Visit 1/screening, Visit 5/week 8. Yes
Secondary Abnormal Involuntary Movement Scale (AIMS) This scale is completed on Visit 1/screening, Visit 5/week 8. Yes
Secondary Columbia-Suicide Severity Rating Scale (C-SSRS) This scale is completed on Visit 1/screening, Visit 2/baseline, Visit 3/week 2, Visit 4/week 4 and Visit 5/week 8. Yes
Secondary Simpson Angus Scale (SAS) This scale is completed on Visit 1/screening, Visit 5/week 8. Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05695131 - Clinical Feasibility & Validation of the Virtual Reality GlenxRose Speech-Language Therapies N/A
Recruiting NCT04117360 - Orthognathic Speech Pathology: Phonetic Contrasts of Patients With Dental Discrepancies Pre- and Post-Treatment Analyses
Completed NCT02288598 - Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering N/A
Completed NCT02490826 - Table to Tablet (T2T): A Novel Intervention Framework for Children With Speech Sound Disorders N/A
Not yet recruiting NCT04528147 - Yi Jin Jing Tiger Roaring Speech Rehabilitation With Real-Time Feedback Technique for PD N/A
Completed NCT02554513 - Apraxia of Speech: Comparison of EPG Treatment (Tx) and Sound Production Treatment (SPT) N/A
Recruiting NCT05876247 - Articulatory Adaptation Following Oral Cancer Treatment
Recruiting NCT05489965 - Gender Disparities in Voice Outcomes After Tracheoesophageal Puncture in Total Laryngectomy Patients (UC Davis)
Completed NCT02752425 - Visual Feedback of Tongue by Ultrasound Echography for Speech Trouble Rehabilitation N/A
Recruiting NCT06443073 - The Mere-measurement Effect of Patient-reported Outcomes N/A
Recruiting NCT05741853 - Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia N/A
Completed NCT04026581 - Real World Testing of a Brain-Computer Interface
Active, not recruiting NCT04937452 - Dopaminergic Therapy for Frontotemporal Dementia Patients Phase 2
Completed NCT02416856 - Brain Connectivity Supporting Language Recovery in Aphasia
Completed NCT01180309 - Lingual Frenum and Articulation of Phonemes N/A
Completed NCT03663972 - Age-related Correlates of Treatment for Late-acquired Sounds N/A
Not yet recruiting NCT04323085 - Speech-in-Noise Treatments for Hypophonia in Parkinson's Disease Phase 2
Completed NCT00125242 - Word-Retrieval Treatment for Aphasia: Semantic Feature Analysis N/A
Completed NCT04966689 - The Effect of Combined Speech and Music-therapy on the Speech Characteristics of People With Parkinson's Disease (PD) N/A
Completed NCT04009811 - A New Membrane Obturator Prothesis Concept for Soft Palate Defects N/A